- Geneva-based company, U.S. headquarters in Boston.
- Priced 6.45 million shares at $15 per share, within its previously-announced range of $14 to $16.
- Raised $97 million in an initial public offering.
Credit Suisse Group AG reiterated an “outperform” rating and set a $27.00 target price on shares of Obseva SA in a report on Tuesday, April 18th. Leerink Swann initiated coverage on shares of Obseva SA in a report on Tuesday, February 21st. They issued an “outperform” rating and a $21.00 price objective on the stock. Finally, Jefferies Group LLC initiated coverage on shares of Obseva SA in a report on Tuesday, February 21st. They issued a “buy” rating and a $21.00 price objective on the stock.
Obseva SA last issued its quarterly earnings data on Thursday, May 18th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.17. Analysts forecast that Obseva SA will post ($2.11) EPS for the current fiscal year.
In the first half of 2017, ObsEva’s lead drug will enter two Phase 3 studies for the treatment of uterine fibroids, a kind of benign tumor, and will enter another Phase 3 trial in 2018 for the treatment of endometriosis, a disorder in which tissue that typically lines the uterus grows outside of the uterus.
The company is also developing a compound for in vitro fertilization, and recently completed a Phase 1 study of a drug to control preterm labor.
